- Home
- SUGP vs TRAW Comparison
SUGP vs TRAW Comparison
Compare SUGP & TRAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUGP
- TRAW
- Stock Information
- Founded
- SUGP 1998
- TRAW 1998
- Country
- SUGP Hong Kong
- TRAW United States
- Employees
- SUGP N/A
- TRAW N/A
- Industry
- SUGP
- TRAW
- Sector
- SUGP
- TRAW
- Exchange
- SUGP NYSE
- TRAW NYSE
- Market Cap
- SUGP 9.6M
- TRAW 8.6M
- IPO Year
- SUGP 2024
- TRAW 2013
- Fundamental
- Price
- SUGP $0.46
- TRAW $1.45
- Analyst Decision
- SUGP
- TRAW
- Analyst Count
- SUGP 0
- TRAW 0
- Target Price
- SUGP N/A
- TRAW N/A
- AVG Volume (30 Days)
- SUGP 151.7K
- TRAW 195.9K
- Earning Date
- SUGP 07-21-2025
- TRAW 08-14-2025
- Dividend Yield
- SUGP N/A
- TRAW N/A
- EPS Growth
- SUGP N/A
- TRAW N/A
- EPS
- SUGP N/A
- TRAW N/A
- Revenue
- SUGP $25,478,980.00
- TRAW $227,000.00
- Revenue This Year
- SUGP N/A
- TRAW $3.81
- Revenue Next Year
- SUGP N/A
- TRAW $30.43
- P/E Ratio
- SUGP N/A
- TRAW N/A
- Revenue Growth
- SUGP 25.07
- TRAW 0.44
- 52 Week Low
- SUGP $0.35
- TRAW $0.97
- 52 Week High
- SUGP $3.25
- TRAW $19.44
- Technical
- Relative Strength Index (RSI)
- SUGP 33.09
- TRAW 44.00
- Support Level
- SUGP $0.43
- TRAW $1.37
- Resistance Level
- SUGP $0.52
- TRAW $1.77
- Average True Range (ATR)
- SUGP 0.07
- TRAW 0.10
- MACD
- SUGP -0.00
- TRAW -0.02
- Stochastic Oscillator
- SUGP 34.63
- TRAW 19.05
About SUGP SU GROUP HLDGS LTD
SU Group Holdings Ltd and its subsidiaries is an integrated security-related services company. The company has two reportable segments: security-related engineering services, and security guarding and screening services and related vocational training services. The company generates the majority of its revenue from the security-related engineering services segment. Geographically operates in Hong Kong, and Other foreign countries, with maximum revenue from Kong Kong.
About TRAW TRAWS PHARMA INC
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.